13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BEP3

    Acronym: 

    BEP3

    ACTRN/NCT /ethics: 

    NCT02582697 Ethics: 384.14

    Scientific title: 

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

    Summary of trial and patient characteristics

    Cancer Type Neuroendocrine
    Trial Type Treatment
    Phase Phase III Tumour Stream Germ cell tumours
    Age Range 11- 45 years Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2014-02-01
    Molecular Target Anticipated End Date 2023-07-01
    Cancer Type Neuroendocrine
    Trial Type Treatment
    Phase Phase III
    Age Range 11- 45 years
    Sex Both
    Molecular Target
    Tumour Stream Germ cell tumours
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2014-02-01
    Anticipated End Date 2023-07-01

    Trial Summary

    The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours

    Lay Summary

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

    Sponsor / Cooperative group

    University of Sydney

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Recruiting
    The Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 70742342 Recruiting
    Flinders Medical Centre Alex Scott alex.scott-hoy@sa.gov.au 08 8204 4830 Recruiting